{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-125351","form_type":"8-K","ticker":"KZR","cik":"0001645666","company_name":"Kezar Life Sciences, Inc.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.091428+00:00","generated_at":"2026-05-30T01:59:18.551562+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Kezar Life Sciences reports Q3 loss $20.3M; halts PALIZADE LN trial over fatal SAEs","bullets":["Net loss $20.3M ($2.78/share) vs $23.1M ($3.18) in Q3 2023; cash, equivalents and marketable securities $148.4M (Dec 31: $201.4M).","Terminated PALIZADE Phase 2b lupus nephritis trial after 4 fatal serious adverse events; full clinical hold by FDA.","PORTOLA autoimmune hepatitis trial: topline data expected H1 2025; IDMC recommended continue; FDA partial hold on open-label extension.","Completed 1-for-10 reverse stock split on Oct 29, 2024 to regain $1.00 minimum bid compliance on Nasdaq.","R&D expenses decreased to $16.2M from $23.7M; G&A to $5.7M from $8.8M due to strategic restructuring."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-125351","json":"https://secwatch.observer/filing/0000950170-24-125351.json","markdown":"https://secwatch.observer/filing/0000950170-24-125351.md","text":"https://secwatch.observer/filing/0000950170-24-125351.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024125351/0000950170-24-125351-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645666/000095017024125351/kzr-20241112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:59:18.551562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}